{"id":24654,"date":"2024-06-11T12:37:54","date_gmt":"2024-06-11T12:37:54","guid":{"rendered":"https:\/\/www.babydetect.be\/paneel-v2\/"},"modified":"2024-10-30T20:55:39","modified_gmt":"2024-10-30T20:55:39","slug":"paneel-v2","status":"publish","type":"post","link":"https:\/\/www.babydetect.be\/nl\/paneel-v2\/","title":{"rendered":"Paneel V2"},"content":{"rendered":"

Het V2-paneel bestaande uit 409 genen of 165 ziekten is in gebruik sinds 25\/02\/2024<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Tak<\/td>\nWanorde<\/td>\nGen<\/td>\nErfenis<\/td>\n<\/tr>\n
Cardiologie<\/td>\nCardiomyopathie, gedilateerd 1 mm of cardiomyopathie hypertrofisch 4<\/td>\nMYBPC3<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nCardiomyopathie, gedilateerde 1S of cardiomyopathie hypertrofisch 1<\/td>\nMYH7<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nLang QT-syndroom 1 of Jervell en Lange-Nielsen-syndroom<\/td>\nKCNQ1<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Cardiologie<\/td>\nLang QT-syndroom 5<\/td>\nKCNE1<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Cardiologie<\/td>\nKort QT-syndroom 3 of Andersen Tawil-syndroom of LQT-syndroom 7<\/td>\nKCNJ2 zei:<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Cardiologie<\/td>\nTimothy-syndroom of LQT8<\/td>\nCACNA1C<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf (CPVT) of LQT4<\/td>\nANK2 zei:<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf (CPVT)\/ CALM-gemedieerde aritmie-syndroom<\/td>\nKALM2<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf (CPVT)\/ CALM-gemedieerde aritmie-syndroom<\/td>\nKALM3<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf, 1 (CPVT)<\/td>\nRYR2<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf, 2 (CPVT)<\/td>\nCASQ2<\/td>\nRecessief<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf, 3<\/td>\nTECRL<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf, 4 (CPVT)<\/td>\nKALM1<\/td>\noverheersend<\/td>\n<\/tr>\n
Cardiologie<\/td>\nVentriculaire tachycardie, catecholaminerge polymorf, 5 (CPVT)<\/td>\nTRDN<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nCYP11A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nCYP11B1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nCYP17A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nCYP21A2<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nHSD3B2 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie<\/td>\nSter<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale bijnierhyperplasie \/ Antley Bixler-syndroom<\/td>\nPOR<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nDUOX1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nDUOXA1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nFOSJE1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nGLIS3<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nGNAS<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nNKX2-1<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nNKX2-5<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nSECISBP2<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nTHRA<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nTHRB<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie<\/td>\nUBR1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (genitopatellaire sd)<\/td>\nKAT6B<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (niet-struma 1)<\/td>\nTSHR<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (hangend)<\/td>\nFOXI1<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (hangend)<\/td>\nKCNJ10 zei:<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (hangend)<\/td>\nSLC26A4<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (dysgenesie van de schildklier)<\/td>\nHHEX<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (dysgenesie van de schildklier)<\/td>\nPAX8<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (dysgenesie van de schildklier)<\/td>\nTUBB1<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-1)<\/td>\nSLC5A5<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-2A)<\/td>\nTPO<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-3)<\/td>\nGS<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-4)<\/td>\nIYD<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-5)<\/td>\nDUOXA2<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nCongenitale hypothyreo\u00efdie (schildklierdyshormonogenese-6)<\/td>\nDUOX2<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nTaaislijmziekte<\/td>\nCFTR<\/td>\nRecessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nTekort in de voorste hypofysefunctie en variabele immunodefici\u00ebntie (DAVID)<\/td>\nNFKB2 NL<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nHyperinsulinisme – hyperammoni\u00ebmie-syndroom (CHI)<\/td>\nLIJM1<\/td>\noverheersend<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nHypofosfatasie, infantiel<\/td>\nALPL<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Endocrinologie<\/td>\nPrimair aldosteronisme, insulten en neurologische afwijkingen (CHI)<\/td>\nCACNA1D<\/td>\ndominant\/ recessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nSyndroom van Crigler-Najjar<\/td>\nUGT1A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nZure sfingomyelinase-defici\u00ebntie<\/td>\nSMPD1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nAlfa1-antitrypsine-defici\u00ebntie<\/td>\nSERPINA1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nAangeboren diarree<\/td>\nDGAT1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nAangeboren diarree<\/td>\nNEUROG3<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nAangeboren diarree<\/td>\nSLC26A3<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nCongenitale natriumdiarree<\/td>\nSLC9A3<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nFamiliale chylomicronemie<\/td>\nLPL<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nFamiliale chylomicronemie<\/td>\nAPOA5<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nFamiliale chylomicronemie<\/td>\nAPOC2<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nFamiliale chylomicronemie<\/td>\nGPIHBP1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nFamiliale chylomicronemie<\/td>\nLMF1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nTekort aan lysosomaal zuurlipase<\/td>\nLIPA<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nAgenesie van de alvleesklier 2<\/td>\nPTF1A<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC1)<\/td>\nATP8B1<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC2)<\/td>\nABCB11 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC3)<\/td>\nABCB4<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC4)<\/td>\nTJP2<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC5)<\/td>\nNR1H4<\/a><\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nProgressieve familiale intrahepatische cholestase (PFIC6)<\/td>\nMYO5B<\/a><\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nSyndroom van Shwachman-Diamond 1<\/td>\nSBDS<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nSyndroom van Shwachman-Diamond 2<\/td>\nEFL1<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nShwachman-Diamond-syndroom-achtig<\/td>\nAdviesprijs 54<\/td>\noverheersend<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nShwachman-Diamond syndroom \/ Beenmergfalen syndroom 3<\/td>\nDNAJC21<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nZeer vroeg optredende inflammatoire darmaandoeningen (VEOIBD)<\/td>\nIL10RA<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nZeer vroeg optredende inflammatoire darmaandoeningen (VEOIBD)<\/td>\nIL10RB<\/td>\nRecessief<\/td>\n<\/tr>\n
Gastro-enterologie<\/td>\nZiekte van Wilson<\/td>\nATP7B<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nBloedarmoede, X-gebonden, met\/zonder neutropenie en\/of bloedplaatjesafwijkingen<\/td>\nGATA1<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nCongenitale protrombinedefici\u00ebntie<\/td>\nF2<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamant-Blackfan-anemie<\/td>\nRPL9<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede<\/td>\nRPL31<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede<\/td>\nTSR2<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 1<\/td>\nRPS19<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 10<\/td>\nRPS26<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 11<\/td>\nRPL26<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 12<\/td>\nRPL15<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 13<\/td>\nRPS29<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 15<\/td>\nRPS28<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan bloedarmoede 16<\/td>\nRPL27<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 17<\/td>\nRPS27<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 18<\/td>\nRPL18<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 19<\/td>\nRPL35<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 20<\/td>\nRPS15A<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 3<\/td>\nRPS24<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 4<\/td>\nRPS17<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 5<\/td>\nRPL35A<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 6<\/td>\nRPL5<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 7<\/td>\nRPL11<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 8<\/td>\nRPS7<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDiamond-Blackfan-bloedarmoede 9<\/td>\nRPS10<\/td>\noverheersend<\/td>\n<\/tr>\n
Hematologie<\/td>\nDyskeratose congenita, X-gebonden<\/td>\nDKC1<\/td>\nX Gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nFactor XIII, A-subeenheid, defici\u00ebntie van<\/td>\nF13A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFactor XIII, B-subeenheid, defici\u00ebntie van<\/td>\nF13B<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nERCC4<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCA<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCB (Vlaams-Braban<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nKANTON FANCC<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCD2<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCE<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCF<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCI<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANCL<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nFANG<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nMAD2L2 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nSLX4<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nFanconi-anemie<\/td>\nUBE2T<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nG6PD-defici\u00ebntie<\/td>\nG6PD<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nHemoglobine stoornissen<\/td>\nHBA1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nHemoglobine stoornissen<\/td>\nHBA2 NL<\/td>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Recessief<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n
Hematologie<\/td>\nHemoglobine stoornissen<\/td>\nHBB<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nHemofilie A<\/td>\nF8<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nHemofilie B<\/td>\nF9<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nPyruvaatkinasedefici\u00ebntie van rode bloedcellen<\/td>\nPKLR<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nTrombotische trombocytopenische purpura, erfelijk<\/td>\nADAMTS13<\/td>\nRecessief<\/td>\n<\/tr>\n
Hematologie<\/td>\nSyndroom van Wiscott-Aldrich<\/td>\nWAS<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Hematologie<\/td>\nSyndroom van Wiscott-Aldrich 2<\/td>\nWIPF1<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSyndroom van Chediak-Higashi<\/td>\nLYST<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nChronische granulomateuze ziekte 1 (CGD)<\/td>\nNCF1<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nChronische granulomateuze ziekte 2 (CGD)<\/td>\nNCF2<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nChronische granulomateuze ziekte 3 (CGD)<\/td>\nNCF4<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nChronische granulomateuze ziekte 4 (CGD)<\/td>\nCYBA<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nChronische granulomateuze ziekte, X-gebonden (CGD)<\/td>\nCYBB<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Immunologie<\/td>\nSyndroom van Griscelli 1<\/td>\nMYO5A<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSyndroom van Griscelli 2<\/td>\nRAB27A<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nHeofagocytaire lymfohistiocytose, familiaal, 2<\/td>\nPRF1<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nHeofagocytaire lymfohistiocytose, familiaal, 3<\/td>\nUNC13D<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nHeofagocytaire lymfohistiocytose, familiaal, 4<\/td>\nSTX11<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nHeofagocytaire lymfohistiocytose, familiaal, 5<\/td>\nSTXBP2 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nADA<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nAK2<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCD247 NL<\/a><\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCD3D<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCD3E<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCD3G<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCIITA<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nCORO1A<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nDCLRE1C<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nFOXN1<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nIL2RG<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nIL7R<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nJAK3<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nLCK<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nLIG4<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nPRKDC<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nPTPRC<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRAc2<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRAG1<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRAG2<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRFX5<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRFXANK<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nRFXAP<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID<\/td>\nZAP70 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID – IMD40<\/td>\nDOK 2<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nSCID – IMD52<\/td>\nLAT<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 1<\/td>\nELANE<\/td>\noverheersend<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 2<\/td>\nGFI1<\/td>\noverheersend<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 3<\/td>\nHAX1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 4 (Dursun-syndroom)<\/td>\nG6PC3<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 5<\/td>\nVPS45<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 6<\/td>\nJAGN1 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 7<\/td>\nCSF3R<\/td>\nRecessief<\/td>\n<\/tr>\n
Immunologie<\/td>\nErnstige congenitale neutropenie 8<\/td>\nAdviesprijs 54<\/td>\noverheersend<\/td>\n<\/tr>\n
Immunologie<\/td>\nWhim-syndroom<\/td>\nCXCR4 zei:<\/td>\noverheersend<\/td>\n<\/tr>\n
Metabo<\/td>\n2-Methylbutyrylglycinurie (SBCAD)<\/td>\nACADSB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\n2,4 Dienoyl-CoA-reductase-defici\u00ebntie<\/td>\nNADK2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\n3-HMG-CoA-synthase-2-defici\u00ebntie<\/td>\nHMGCS2 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\n3-Hydroxy-3-Methyglutaaracidurie (HMGCoAliase)<\/td>\nHMGCL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\n3-methylcrotonyl-CoA-carboxylasedefici\u00ebntie (3MCC)<\/td>\nMCCC1 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\n3-methylcrotonyl-CoA-carboxylasedefici\u00ebntie (3MCC)<\/td>\nMCCC2 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nACAD9-defici\u00ebntie<\/td>\nACAD9 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nArgininemie<\/td>\nARG1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nArgininosuccinic Acidurie<\/td>\nASL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nBiotinidase-defici\u00ebntie<\/td>\nBTD<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nVertakte keten ketozuurdehydrogenasekinasedefici\u00ebntie<\/td>\nBCKDK<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSyndroom van Brown-Vialetto-Van Laere 1<\/td>\nSLC52A3<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSyndroom van Brown-Vialetto-Van Laere 2<\/td>\nSLC52A2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCarnitine Acylcarnitine Translocase-defici\u00ebntie<\/td>\nSLC25A20<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCarnitine Palmitoyltransferase Type IDeficiency (CPT1)<\/td>\nCPT1A<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCarnitine palmitoyltransferase type II-defici\u00ebntie (CPT2)<\/td>\nCPT2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCarnitine Opname Defect\/CarnitineTransport Defect<\/td>\nSLC22A5<\/td>\n\n\n\n\n\n
Recessief<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n
Metabo<\/td>\nCerebraal creatinedefici\u00ebntie-syndroom<\/td>\nGAMT<\/td>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Recessief<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n
Metabo<\/td>\nCerebraal creatinedefici\u00ebntie-syndroom<\/td>\nGATM<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCerebraal creatinedefici\u00ebntie-syndroom<\/td>\nSLC6A8<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Metabo<\/td>\nCitrullinemie, type I<\/td>\nASS1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCitrullinemie, type II<\/td>\nSLC25A13<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGecombineerde malonische en methylmalonacidurie (CMAMMA)<\/td>\nACSF3<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nCPS1-defici\u00ebntie<\/td>\nCPS1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nDihydrolipoamide-dehydrogenase-defici\u00ebntie<\/td>\nTOS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFructose-1,6-bifosfatase-defici\u00ebntie<\/td>\nFBP1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFructose-intolerantie, erfelijk<\/td>\nALDOB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGalactosemie<\/td>\nSTORM<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGalactosemie<\/td>\nGALK1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGalactosemie<\/td>\nGALT<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGalactosemie IV<\/td>\nKANTON GALM<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nZiekte van Gaucher type 1<\/td>\nGBA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMalabsorptie van glucose\/galactose<\/td>\nSLC5A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlutaaracidurie type I<\/td>\nGCDH (Hongarije)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycine encefalopathie<\/td>\nAMT<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycine encefalopathie<\/td>\nGLDC<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type 0A<\/td>\nGYS2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type 0B<\/td>\nGYS1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type IA<\/td>\nG6PC<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type IB\/IC<\/td>\nSLC37A4<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type III<\/td>\nAGL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type IXA<\/td>\nPHKA2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type IXB<\/td>\nPHKB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type IXC<\/td>\nPHKG2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type VI<\/td>\nPYGL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nGlycogeenstapelingsziekte type XI (Fanconi-Bickel)<\/td>\nSLC2A2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHolocarboxylasesynthase-defici\u00ebntie<\/td>\nHLCS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHomocystinurie<\/td>\nCBS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHomocystinurie<\/td>\nMTHFR<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHomocystinurie<\/td>\nMTR<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHomocystinurie (CblE)<\/td>\nMTRR<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nZiekte van de jager (MPS II)<\/td>\nIDS<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Metabo<\/td>\nZiekte van Hurler (MPS I)<\/td>\nIDUA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHypermethioninemie<\/td>\nADK<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHypermethioninemie<\/td>\nAHCY<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nHypermethioninemie<\/td>\nMAT1A<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Metabo<\/td>\nHyperornithinemie – hyperammoni\u00ebmie – homocitrullinurie-syndroom (HHH)<\/td>\nSLC25A15<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nIsobutyrylglycinurie<\/td>\nACAD8<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nIsovalerische acidemie<\/td>\nIVD (Medische Verklaring)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nL-3 hydroxyacyl-CoADehydrogenase-defici\u00ebntie met lange keten (LCHAD)<\/td>\nHADHA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nL-3 hydroxyacyl-CoADehydrogenase-defici\u00ebntie met lange keten (trifunctionele eiwitdefici\u00ebntie)<\/td>\nHADHB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMalonische acidurie<\/td>\nMLYCD<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSyndroom van Maroteaux-Lamy (MPS VI)<\/td>\nARSB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMiddellange keten Acyl-CoA-dehydrogenasedefici\u00ebntie (MCAD)<\/td>\nACADM<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMiddellange\/korte-keten L-3-hydroxyacylCoADehydrogenase-defici\u00ebntie<\/td>\nHADH<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nABCD4<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nHCFK1<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nLMBRD1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nMCEE<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nMMACHC (Hongarije)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nMMADHC<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nMMUT<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie<\/td>\nTCN2<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie (CblA)<\/td>\nMMAA (MMAA)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMethylmalonzuuracidemie (CblB)<\/td>\nMMAB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nZiekte van Morquio (MPS IVA)<\/td>\nGALNS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMSUD<\/td>\nBCKDHA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMSUD<\/td>\nBCKDHB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMSUD<\/td>\nDBT<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMultipele acyl-coa-dehydrogenasedefici\u00ebntie (MADD)<\/td>\nETFA (Engelstalig)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMultipele acyl-coa-dehydrogenasedefici\u00ebntie (MADD)<\/td>\nETFB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMultipele acyl-coa-dehydrogenasedefici\u00ebntie (MADD)<\/td>\nETFDH<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nMultipele acyl-coa-dehydrogenasedefici\u00ebntie (MADD)<\/td>\nFLAD1 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nNAGS-tekort<\/td>\nNAGS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nOTC-defici\u00ebntie<\/td>\nOTC<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (BH4)<\/td>\nGCH1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (BH4)<\/td>\nPrintplaat 1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (BH4)<\/td>\nPTS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (BH4)<\/td>\nQDPR<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (Hyper-Phe, mild)<\/td>\nDNAJC12<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nFenylketonurie (PKU)<\/td>\nPAK<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nZiekte van Pompe<\/td>\nGAA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nPropionzuuracidemie<\/td>\nPCCA<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nPropionzuuracidemie<\/td>\nPCCB<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nPyridoxine-afhankelijke epilepsie<\/td>\nALDH7A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nPyridoxine-afhankelijke epilepsie<\/td>\nPNPO<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nRiboflavine-defici\u00ebntie<\/td>\nSLC52A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nRiboflavinedefici\u00ebntie, inspanningsintolerantie<\/td>\nSLC25A32<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSCOT-defici\u00ebntie<\/td>\nOXCT1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nDefect aan de biosynthese van serine<\/td>\nPHGDH<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nDefect aan de biosynthese van serine<\/td>\nPSAT1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nDefect aan de biosynthese van serine<\/td>\nPSPH (Neppe)<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSerine transporter defect<\/td>\nSLC1A4<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nAcyl-CoA-dehydrogenasedefici\u00ebntie met korte keten<\/td>\nACADS<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSluw (MPSVII)<\/td>\nGUSB<\/td>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Recessief<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n
Metabo<\/td>\n\u00df-Ketothiolase-defici\u00ebntie<\/td>\nACAT1<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nSucrase-isomaltase-defici\u00ebntie<\/td>\nSI<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nTyrosinemie 1<\/td>\nFAH<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nTyrosinemie 2<\/td>\nHPD<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nTyrosinemie 3<\/td>\nTAT<\/td>\nRecessief<\/td>\n<\/tr>\n
Metabo<\/td>\nVLCAD<\/td>\nACADVL<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nAlport-syndroom type 1, X-gekoppeld<\/td>\nCOL4A5<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Nefrologie<\/td>\nSyndroom van Alport type 2<\/td>\nCOL4A4<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nSyndroom van Alport type 2 en 3<\/td>\nCOL4A3 NL<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Nefrologie<\/td>\nCongenitaal nefrotisch syndroom, Fins<\/td>\nNPHS1<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nCystinose, nefropathisch<\/td>\nCTNS<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nErfelijke nefrogene diabetes insipidus (NDI)<\/td>\nAQP2<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Nefrologie<\/td>\nErfelijke nefrogene diabetes insipidus (NDI)<\/td>\nAVPR2<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Nefrologie<\/td>\nHypofosfatemische rachitis, X-gebonden<\/td>\nPHEX<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPrimaire Oxalurie type 1<\/td>\nAGXT<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPrimaire Oxalurie type 2<\/td>\nGRHPR<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPrimaire Oxalurie type 3<\/td>\nHOGA1<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type I (PHA1a)<\/td>\nNR3C2<\/td>\noverheersend<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type I (PHA1b)<\/td>\nSCNN1A<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type I (PHA1b)<\/td>\nSCNN1B<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type I (PHA1b)<\/td>\nSCNN1G<\/td>\nRecessief<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type IIB (PHA2B)<\/td>\nWNK4<\/td>\noverheersend<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type IIC (PHA2C)<\/td>\nWNK1<\/td>\noverheersend<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type IID (PHA2D)<\/td>\nKLHL3<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Nefrologie<\/td>\nPseudohypoaldosteronisme, type IIE (PHA2E)<\/td>\nCUL3<\/td>\noverheersend<\/td>\n<\/tr>\n
Neurologie<\/td>\nAromatische L-aminozuurdecarboxylasedefici\u00ebntie<\/td>\nDDC<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nAtaxie met vitamine E-tekort<\/td>\nTTPA<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nHersenen dopamine-serotonine vesiculaire transportziekte<\/td>\nSLC18A2<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nDecrebrale defici\u00ebntie van foliumzuurtransport<\/td>\nFOLR1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nCeroide Lipofuscinose type 2 (CLN2)<\/td>\nTPP1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nDe Vivo ziekte<\/td>\nSLC2A1<\/td>\ndominante\/ zeldzame AR<\/td>\n<\/tr>\n
Neurologie<\/td>\nOntwikkelings- en epileptische encefalopathie 82\/ GOT2-defici\u00ebntie<\/td>\nGOT2<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nDopamine b\u00e8ta-hydroxylase-defici\u00ebntie<\/td>\nDBH<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nDystonie dopa responsief<\/td>\nSPR<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nepilepsie, vroeg optredend, vitamine B6-afhankelijk; Epvb6d<\/td>\nPLPBP<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nErfelijke hyperekplexie 1<\/td>\nGLRA1<\/td>\nrecessief en dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nErfelijke hyperekplexie 2<\/td>\nGLRB<\/td>\nrecessief en dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nErfelijke hyperekplexie 3<\/td>\nSLC6A5<\/td>\nrecessief en zeldzaam dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nZiekte van Menkes<\/td>\nATP7A<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Neurologie<\/td>\nMetachromatische leukodystrofie<\/td>\nARSA<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren<\/td>\nGMPPB<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren<\/td>\nLAMA5 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren<\/td>\nMACF1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren<\/td>\nRPH3A<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 10<\/td>\nDOK7<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 11<\/td>\nGFPT1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 11<\/td>\nRAPSN<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 13, met tubulaire aggregaten<\/td>\nDPAGT1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 14<\/td>\nALG2<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 15<\/td>\nALG14<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 17<\/td>\nLRP4 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 18<\/td>\nKLIK 25<\/td>\noverheersend<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 19<\/td>\nCOL13A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 1A langzaam kanaal of 1B snel kanaal<\/td>\nCHRNA1<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 20, presynaptisch<\/td>\nSLC5A7<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 21, presynaptisch<\/td>\nSLC18A3<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 22<\/td>\nVOORBEREIDING<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 23, presynaptisch<\/td>\nSLC25A1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 24, presynaptisch<\/td>\nMYO9A<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 25<\/td>\nVAMP1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 2A, slow-channel<\/td>\nCHRNB1 NL<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 3B, snel kanaal<\/td>\nCHRND<\/td>\nrecessief\/ dominant<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 4c,<\/td>\nACHRE<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 5<\/td>\nCOLQ<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 6, presynaptisch<\/td>\nBABBELEN<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 7, presynaptisch<\/td>\nSYT2 NL<\/td>\noverheersend<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 8, postsynaptisch<\/td>\nAGRN<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, 9, geassocieerd met acetylcholinereceptordefici\u00ebntie<\/td>\nMUSKUS<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, aangeboren, met epidermolysis bullosa<\/td>\nPLEC<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nMyasthenisch syndroom, MUNC13-1<\/td>\nUNC13-1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nNeuropathie, erfelijke motorische en sensorische, type VIC, met optische atrofie<\/td>\nPDXK<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nSyndroom van Segawa<\/td>\n\u00de<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nSyndroom van Smith-Lemli-Opitz<\/td>\nDHCR7 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nSpinale musculaire atrofie<\/td>\nSMN1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nSpinale musculaire atrofie<\/td>\nSMN2<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nThiaminemetabolisme disfunctie syndroom 2 (biotine- of thiamine-responsieve encefalopathie type 2)<\/td>\nSLC19A3<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nThiaminemetabolisme disfunctiesyndroom 4 (progressieve polyneuropathie type)<\/td>\nSLC25A19<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nThiaminemetabolisme disfunctiesyndroom 5 (episodische encefalopathie type)<\/td>\nTPK1<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nThiamine-responsief megaloblastisch anemie-syndroom<\/td>\nSLC19A2<\/td>\nRecessief<\/td>\n<\/tr>\n
Neurologie<\/td>\nX-Adrenoleukodystrofie<\/td>\nABCD1<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
Onco \/ OPH<\/td>\nRetinoblastoom<\/td>\nRB1<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nFZD4 NL<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nKIF11 zei:<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nLRP5<\/td>\nRecessief<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nRCBTB1<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nTSPAN12<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nFamiliale exsudatieve vitreoretinopathie (FEVR)<\/td>\nZNF408 zei:<\/td>\noverheersend<\/td>\n<\/tr>\n
OPH<\/td>\nPrimair aangeboren glaucoom<\/td>\nCYP1B1<\/td>\nRecessief<\/td>\n<\/tr>\n
OPH<\/td>\nPrimair aangeboren glaucoom<\/td>\nLTBP2<\/td>\nRecessief<\/td>\n<\/tr>\n
OPH<\/td>\nErnstige retinale dystrofie in de vroege kinderjaren (SECORD)<\/td>\nRPE65 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nACTH-defici\u00ebntie, ge\u00efsoleerd<\/td>\nTBX19<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nAgammaglobulinemie 7, autosomaal recessief<\/td>\nPIK3R1 NL<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nAgammaglobulinemie, X-gebonden<\/td>\nBTK<\/td>\nX Gekoppeld<\/td>\n<\/tr>\n
 <\/td>\nAuto-immuun lymfoproliferatief syndroom<\/td>\nFAS<\/td>\noverheersend<\/td>\n<\/tr>\n
 <\/td>\nSyndroom van Bachman-Bupp (BABS)<\/td>\nODC1<\/td>\noverheersend<\/td>\n<\/tr>\n
 <\/td>\nBeenmergfalen syndroom 4<\/td>\nMYSM1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nKoolzuuranhydrase Va-defici\u00ebntie, hyperammoni\u00ebmie als gevolg van (CA5AD)<\/td>\nCA5A<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nAangeboren aandoening van glycosylering, type IIn<\/td>\nSLC39A8<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nCorticosteronmethyloxidase type I-defici\u00ebntie<\/td>\nCYP11B2<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nFanconi-anemie, complementatiegroep D1<\/td>\nBRCA2<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nFanconi-anemie, complementatiegroep J<\/td>\nBRIP1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nFanconi-anemie, complementatie groep W<\/td>\nRFWD3<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nGlucocortico\u00efddefici\u00ebntie 2 (GCCD2)<\/td>\nMRAP<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nGlucocortico\u00efddefici\u00ebntie 4 met of zonder mineralocortico\u00efddefici\u00ebntie<\/td>\nNNT<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nGRIN2B-gerelateerde neurologische ontwikkelingsstoornis (GRIN2B-NDD)<\/td>\nGRIN2B<\/td>\noverheersend<\/td>\n<\/tr>\n
 <\/td>\nErfelijke hyperekplexie 4<\/td>\nATAD1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nHyper-IgE recidiverend infectiesyndroom 2, autosomaal recessief<\/td>\nDOK 8<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nSyndroom van Imerslund-Grasbeck 1<\/td>\nCUBN<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nSyndroom van Imerslund-Grasbeck 2<\/td>\nAMN<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nImmunodefici\u00ebntie 23<\/td>\nPGM3<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nImmunodefici\u00ebntie 24<\/td>\nCTPS1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nimmunodefici\u00ebntie 63 met lymfoproliferatie en auto-immuniteit; IMD63 zei:<\/td>\nIL2RB<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nImmunodefici\u00ebntie 67<\/td>\nIRAK4 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nImmunodefici\u00ebntie 71 met ontstekingsziekte en congenitale trombocytopenie<\/td>\nARPC1B<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nImmunodysregulatie, polyendocrinopathie en enteropathie, X-gebonden (IPEX)<\/td>\nFOXP3<\/td>\nX-gekoppeld<\/td>\n<\/tr>\n
 <\/td>\nIntrinsieke factordefici\u00ebntie (IFD)<\/td>\nCBLIF<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nJohanson-Blizzard-syndroom (pancreatitis achylia – een van de vele symptomen)<\/td>\nUBR1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nDefici\u00ebntie van leukocytenadhesie, type I (LAD)<\/td>\nITGB2<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nLymfoproliferatief syndroom, X-gebonden, 1<\/td>\nSH2D1A<\/td>\nX Gekoppeld<\/td>\n<\/tr>\n
 <\/td>\nLymfoproliferatief syndroom, X-gebonden, 2<\/td>\nXIAP<\/td>\nX Gekoppeld<\/td>\n<\/tr>\n
 <\/td>\nLysynurische eiwitintolerantie<\/td>\nSLC7A7 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nMevalonische acidurie<\/td>\nMVK<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nMolybdeen-cofactordefici\u00ebntie, complementatiegroep A<\/td>\nMOCS1<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nMucopolysaccharidose IIIa (MPS IIIb)<\/td>\nNAGLU<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nMucopolysaccharidose IIIa (MPS IIIc)<\/td>\nHGSNAT<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nMucopolysaccharidose IIIa (MPSIIIa)<\/td>\nSGSH<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nNijmeegs breuksyndroom<\/td>\nNBN<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nZiekte van Norrie<\/td>\nNDP<\/td>\nX gekoppeld<\/td>\n<\/tr>\n
 <\/td>\nOsteopetrose, autosomaal recessief 4<\/td>\nCLCN7 zei:<\/td>\nRecessief<\/td>\n<\/tr>\n
 <\/td>\nOsteopetrose, autosomaal recessief 7<\/td>\nTNFRSF11A<\/td>\nRecessief<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Het V2-paneel bestaande uit 409 genen of 165 ziekten is in gebruik sinds 25\/02\/2024 Tak Wanorde Gen Erfenis Cardiologie Cardiomyopathie, gedilateerd 1 mm of cardiomyopathie hypertrofisch 4 MYBPC3 overheersend Cardiologie Cardiomyopathie, gedilateerde 1S of cardiomyopathie hypertrofisch 1 MYH7 overheersend Cardiologie Lang QT-syndroom 1 of Jervell en Lange-Nielsen-syndroom KCNQ1 dominant\/ recessief Cardiologie Lang QT-syndroom 5 KCNE1…<\/p>\n","protected":false},"author":4,"featured_media":23922,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[],"_links":{"self":[{"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/posts\/24654"}],"collection":[{"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/comments?post=24654"}],"version-history":[{"count":1,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/posts\/24654\/revisions"}],"predecessor-version":[{"id":24655,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/posts\/24654\/revisions\/24655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/media\/23922"}],"wp:attachment":[{"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/media?parent=24654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/categories?post=24654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.babydetect.be\/nl\/wp-json\/wp\/v2\/tags?post=24654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}